<DOC>
	<DOCNO>NCT01221298</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics , antiviral activity ABT-450 ritonavir ( ABT-450/r ) dose combination ABT-072 ribavirin ( RBV ) treatment-naïve participant genotype 1 chronic hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>A Pilot Study Evaluate Safety , Tolerability , Pharmacokinetics , Antiviral Activity ABT-450 With Ritonavir ( ABT-450/r ) Dosed Combination With ABT-072 Ribavirin ( RBV )</brief_title>
	<detailed_description>This Phase 2a multicenter , open-label , single arm , combination treatment study regimen ABT-450/r/ABT-072 , ribavirin ( RBV ) hepatitis C virus ( HCV ) genotype 1- ( 1a 1b ) infect treatment-naïve participant .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Chronic hepatitis C , genotype 1 infection interleukin 28B ( IL28B ) rs12979860 genotype C/C . Liver biopsy within 3 year histology consistent hepatitis C virus ( HCV ) induce liver damage , evidence cirrhosis liver pathology due cause chronic HCV . Treatment naïve male female age 18 65 . Females must postmenopausal least 2 year surgically sterile . Be condition general good health , perceive investigator , hepatitis C virus infection . Body mass index 18 &lt; 35 kg/m^2 . Significant sensitivity drug . Use herbal supplement within 2 week prior study drug dosing . Positive screen certain drug alcohol . Positive hepatitis B surface antigen antihuman immunodeficiency virus ( HIV ) antibody . Use strong cytochrome P450 3A ( CYP3A ) , cytochrome P450 2C8 ( CYP2C8 ) , organic anion transport polypeptide 1B1 ( OATP1B1 ) enzyme inducer inhibitor within 1 month dosing . Prior treatment investigational commercially available antihepatitis C virus agent . Abnormal laboratory test . Cirrhosis extensive bridging fibrosis . History cardiac disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>